

Multi-System Inflammatory Syndrome in Children Presented with Persistent Respiratory Alkalosis: A Case Report

Heba Alameer¹, Sajjad Alkadhem¹, Fatimah Almuhanha¹, Mahdi Alsuwailem¹, Abdullah Alkhawajah¹,
Ali Bumejdad¹, Fadi Busaleh¹, Maali Alali¹, Abdullah Al Muaibid².
Paediatric Department, Maternity and Children Hospital of Alahsa, Saudi Arabia ¹
Collage of Medicine, University of Albaha, Saudi Arabia²

Abstract:- Multi-System Inflammatory Syndrome in Children (MIS-C) was identified by the US Centers for Disease Control and Prevention (CDC) as a person <21 presenting with fever ≥ 24 hour with at least two multisystemic-organ involvement, including predominantly gastrointestinal and cardiovascular symptoms associated with high inflammatory markers. Frequently, these manifestations may correspond to severe acute respiratory syndrome due to coronavirus-2 (SARS-CoV-2), which represent a challenge for any pediatrician or clinicians. In this report, we presented a five-year-old boy with persistent respiratory alkalosis. Moreover, we demonstrated the management protocol for such cases, which will aid in reducing the burden of such challenges.

Keywords: Case report, SARS-CoV-2, COVID-19, Saudi Arabia

INTRODUCTION

In March 2020, the World Health Organization (WHO) was declared the coronavirus disease of 2019 (COVID-19) as a pandemic, which is the responsible cause of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Fortunately, children represent only 2% of the whole case since the onset of the coronavirus (COVID-19) pandemic with milder symptoms compared to adults [2]. Later, in mid-April, Riphagen S. et al. reported eight children sharing Kawasaki shock syndrome-related features similar to SARS-CoV-2, such as delayed reaction [3]. These symptoms were subsequently reported worldwide; thus, Multi-System Inflammatory Syndrome in Children (MIS-C) was identified by the US Centers for Disease Control and Prevention (CDC) as a person <21 presenting with fever ≥ 24 hr with at least two multisystemic-organ involvement, including predominantly gastrointestinal and cardiovascular symptoms associated with high inflammatory markers, in addition to a history of contact to COVID-19 cases or history of recent infection [4]. In contrast, these variant manifestations corresponded to (SARS-CoV-2) [5], which represent a challenge for any pediatrician or clinicians. In this report, we present a five-year-old boy with persistent respiratory alkalosis.

CASE PRESENTATION

A 5-year-old boy, who was previously healthy, came to the emergency department with a history of persistent fever for six days associated with headache, fatigue, abdominal pain, maculopapular inguinal rash, and decreased oral intake and activity. SARS-COV-2 infection

was detected approximately two days ago. **Table 1** shows the clinical and laboratory characteristics of the child. The patient was lethargic and had appeared sick. Vital signs were febrile (38.9°C), borderline normal blood pressure (88/55 mmHg), with normal respiratory rate, SPO2 and heart rate. Initial laboratory findings showed normal WBCs, mild increase in neutrophil count, anemia, mild thrombocytopenia, hyponatremia, hypokalemia, mild hypochloremia, hypoalbuminemia, and elevated LDH. Coagulation profile was within the reference range. However, the D-dimer was elevated, the inflammatory markers revealed ESR (77 mm/hour), CRP (>27 mg/dL), ferritin (438.4 ng/mL), and the CKMB was (33.4 mg/dL). Initial venous blood gas showed respiratory alkalosis, Ph (7.54), CO₂ (26.6 mmHg/L), and HCO₃ (26.2 mmol/L); therefore, the patient was admitted to the Pediatrics ICU as a case of SARS-COV-2 with MIS-C. According to the Saudi MOH guidelines protocol for the treatment of MIS-C, ceftazidime, vancomycin, IVIG 2g/kg/dose, methylprednisolone (10mg/kg/dose), enoxaparin, tocilizumab, aspirin, and favipiravir were initiated. After a single dose of IVIG the patient began to improve; fever decreased on the second day of admission. During admission to PICU, despite the sufficient hydration & chemistry of the blood, the patient demonstrated a reduction in the blood pressure with wide pulse pressure (98/35). Therefore, the patient was administered norepinephrine to maintain the blood pressure; moreover, potassium chloride was given to correct the hypokalemia; then patient became stable and improved, so norepinephrine weaned gradually after that patient shifted to an isolation room in the general pediatric ward. Then, he stayed in PICU for five days & a full hospital stay about eight days. Finally, he discharged home in good condition with a tapering dose of prednisolone and aspirin with cardiology and nephrology outpatient department's (OPD) follow up regarding persistent respiratory alkalosis and hypokalemia with renal ultrasound to exclude renal diseases.

DISCUSSION

Our patient fulfilled the CDC criteria in terms of MIS-C [4]. Evidence of current or recent SARS-CoV-2 infection is confirmed by reverse transcription-polymerase chain reaction (RT-PCR), serology test, or exposure to a suspected or confirmed COVID-19 case within the four weeks before the onset of symptoms. We considered our patient as a case of MIS-C, and we follow the Saudi MOH

guideline for treating MIS-C by pulse therapy of methylprednisolone (ranging from 2 to 30 mg/kg/day), intravenous immunoglobulin, 1 to 2 grams/kg, enoxaparin, tocilizumab, aspirin, and favipiravir.

MIS-C occurs as the delayed latent reaction to SARS-CoV-2 that triggers the immune system to generate antibodies that are the responsible cause of cytokines storm [6]. We assumed that the cytokines storm contributes to metabolic acidosis of SARS-CoV-2 patients; however, our patient's presented by persistent respiratory alkalosis associated with hypokalemia and hypotension with wide pulse pressure despite adequate hydration. All of these indicators raised our suspicion of other underlying diseases affecting the acid-base balance, especially renal diseases such as Bartter syndrome and Gitelman syndrome (GS) [7,8]. Further investigations are needed to elucidate the pathophysiological mechanism of MIS-C in relation to other associated inherited renal diseases in pediatrics ages group.

Acknowledgement: None

Conflict of Interest: None

Funding Source: None

REFERENCES

- [1] Valencia DN. Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. *Cureus* 2020. <https://doi.org/10.7759/cureus.7386>.
- [2] Posfay-Barbe KM, Wagner N, Gauthey M, Moussaoui D, Loevy N, Diana A, et al. COVID-19 in children and the dynamics of infection in families. *Pediatrics* 2020. <https://doi.org/10.1542/peds.2020-1576>.
- [3] Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet* 2020;395:1607-8. [https://doi.org/10.1016/S0140-6736\(20\)31094-1](https://doi.org/10.1016/S0140-6736(20)31094-1).
- [4] Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. Children and adolescents. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2021680>.
- [5] Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, et al. Characteristics, Cardiac Involvement, and Outcomes of Multisystem Inflammatory Syndrome of Childhood Associated with severe acute respiratory syndrome coronavirus 2 Infection. *J Pediatr* 2020. <https://doi.org/10.1016/j.jpeds.2020.06.044>.
- [6] Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. *JCI Insight* 2019. <https://doi.org/10.1172/jci.insight.123158>.
- [7] Chhetri S, Khamis F, Pandak N, Al Khalili H, Said E, Petersen E. A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm). *IDCases* 2020;21:e00829. <https://doi.org/10.1016/j.idcr.2020.e00829>.
- [8] Cunha T da S, Heilberg IP. Bartter syndrome: causes, diagnosis, and treatment. *Int J Nephrol Renovasc Dis* 2018; Volume 11:291-301. <https://doi.org/10.2147/IJNRD.S155397>.

Table 1: Clinical and laboratory characteristics

| Investigations | Reference Range | Patient Result | |
|------------------------------------|-------------------------------|----------------|-------|
| | | Initial | Final |
| <u>Complete blood count</u> | | | |
| Total white blood cells | 4.5-13.5 ×10 ³ /μL | 9.41 | 23.93 |
| Neutrophil count | 1.5-8.5 ×10 ³ /μL | 8.36 | 22.18 |
| Lymphocyte count | 1.5-6.5 ×10 ³ /μL | 0.71 | 1.48 |
| Hemoglobin | 12.5-13.7 g/dL | 9.9 | 9.4 |
| Platelets | 150-350 ×10 ³ /μL | 136 | 210 |
| <u>Biochemistry</u> | | | |
| Random serum glucose | 7-200 mg/dL | 84.7 | 130 |
| Creatinine | 44-88 μmol/L | 53 | 53.08 |
| Urea | 1.7-7.1 mmol/L | 4.2 | 3.0 |
| calcium | 2.1-2.5 mmol/L | 2.27 | 1.96 |
| sodium | 135-145 mmol/L | 132 | 139 |
| Potassium | 3.5-5 mmol/L | 4.11 | 3.3 |
| Chloride | 97-107 mmol/L | 93.0 | 99 |
| Magnesium | 0.63-1.05 mmol/L | 1.00 | 0.87 |
| Phosphorus | 0.78-1.42 mmol/L | 1.36 | 1.2 |
| LDH | 100-190 units/L | 306 | 213 |
| Total serum bilirubin | 0.2-1.5mg/dL | 0.460 | |
| Direct bilirubin | 0.0-0.2 mg/dL | 0.242 | |

| | | | |
|------------------------------------|-------------------|-----------|-------|
| Albumin | 34.0-50.0 g/L | 29.0 | 29.2 |
| AST | 13-35 unit/L | 38.2 | 15 |
| ALT | 10-30 unit/L | 19.9 | 20 |
| Alkaline phosphatase | 100-320 units/L | 91.0 | 74 |
| <u>Blood Gases</u> | | | |
| pH | 7.35-7.45 | 7.544 | 7.435 |
| Hco3 | 21-28 mmol/L | 26.2 | 24.6 |
| PCo2 | 35-45 mmHg/L | 27.6 | 36.7 |
| <u>Coagulation Profile</u> | | | |
| PT | 11.0-13.5 seconds | 11.8 sec. | |
| PTT | 30-40 seconds | 37.8 sec. | |
| INR | 0.8-1.1 | 1.03 | |
| <u>Inflammatory Markers</u> | | | |
| ESR | 0.0-20 mm/hour | 77 | |
| C-RP | 0.0-0.9 mg/dL | >27.0 | |
| Ferritin | 7-140 ng/mL | 438.4 | |
| <u>Cardiac enzymes</u> | | | |
| Troponins | <0.2ng/ml | NOT TAKEN | |
| CKMB | 0-25U/L | 33.4 | |
| <u>Cultures, Serology</u> | | | |
| COVID-19 PCR | Positive twice | | |
| Blood culture | Negative | | |
| Urine Culture | | | |
| Cytomegalovirus antibodies | | | |
| Epstein-Barr virus antibodies | | | |
| Herpes Simplex Virus Antibodies | | | |